Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 43.88B P/E 11.49 EPS this Y - Ern Qtrly Grth 66.90%
Income 431.18B Forward P/E 23.42 EPS next Y - 50D Avg Chg -12.00%
Sales 3.35T PEG - EPS past 5Y - 200D Avg Chg -17.00%
Dividend 1,299.00% Price/Book 0.01 EPS next 5Y 0.58% 52W High Chg -31.00%
Recommedations 2.30 Quick Ratio 0.91 Shares Outstanding 3.15B 52W Low Chg -
Insider Own 0.01% ROA 2.65% Shares Float 3.14B Beta 1.10
Inst Own 3.07% ROE 8.69% Shares Shorted/Prior 8.40M/6.24M Price 13.82
Gross Margin 70.11% Profit Margin 12.89% Avg. Volume 2,193,181 Target Price 20.37
Oper. Margin 16.04% Earnings Date - Volume 1,912,278 Change -0.29%
Takeda Pharmaceutical Company L News
10/27/21 Closing Gaps and Restoring Trust: Building on UNGA76 to Strengthen Global Health Systems
10/27/21 Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout
10/27/21 Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
10/27/21 Novavax files for its first COVID-19 vaccine authorization in UK
10/27/21 BioLife Plasma goes green in Tukwila with first all-electric donation center
10/19/21 Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
10/19/21 Calithera Buys Two Oncology Candidates From Takeda For $45M
10/14/21 Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
10/13/21 BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
10/12/21 A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics
10/07/21 UPDATE 1-Japan secures 120 mln more Pfizer COVID-19 vaccine doses for next year
10/07/21 FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
10/06/21 The Petri Dish: Takeda taps Selecta for gene therapy, BICO makes another buy
10/06/21 Takeda Stock Nears Two-Year Low After This Issue Shuttered Two Narcolepsy Tests
10/06/21 Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
10/06/21 Takeda Discontinues Two Mid-Stage Narcolepsy Trials
10/05/21 Takeda Provides Update on TAK-994 Clinical Program
10/01/21 Japan Moderna Supplier Takeda Plans Its Second-Biggest Yen Bond
09/30/21 The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Chatroom

User Image Romeomustfly Posted - 11 hours ago

$LVTX also coming into focus $TAK buying company focusing onto gammadelta T cells

User Image STCKPRO Posted - 12 hours ago

$TAK NEW ARTICLE : Takeda Pharmaceutical FQ2 Earnings Preview https://www.stck.pro/news/TAK/17147750

User Image hyperbolenarian Posted - 12 hours ago

$TAK 13.83s got filled this morning anything under $15 is ez money imo.

User Image Newsfilter Posted - 13 hours ago

$TAK Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout https://newsfilter.io/a/0a6c4af5ed60deaf2b28a484f73c99a8

User Image STCKPRO Posted - 13 hours ago

$TAK NEW ARTICLE : Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout https://www.stck.pro/news/TAK/17145567

User Image teamstevo Posted - 13 hours ago

$TAK One of the biggest pharma companies in the world, great dividend. Buy all you can long term holders. Will see 20+ next year

User Image briefingcom Posted - 14 hours ago

$TAK agrees to acquire GammaDelta Therapeutics https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20211027091743TAK

User Image NevadaKid Posted - 14 hours ago

$CEMI Chembio Diagnostics Substantially undervalued. F.D.A. approval on its Covid/Flu test could happen at any time which will double/triple the share price. Last time it received approval on one of its test it traded over 600,000,000 shares in two days and hit $7.12 because the shorts had oversold it. Company is currently hiring for more than 100 positions to meet the demands of its tremendous growth. Potential takeover target at $15+. Possible suitors are $JNJ, $TAK, $DGX and $AZN. Buy a few shares on before the next p.r.

User Image otcdynamics Posted - 16 hours ago

$TAK Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors https://www.otcdynamics.com/tak-takeda-to-acquire-gammadelta-therapeutics-to-accelerate-development-of-allogeneic-t-cell-therapies-addressing-solid-tumors

User Image STCKPRO Posted - 16 hours ago

$TAK NEW ARTICLE : Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors https://www.stck.pro/news/TAK/17139118

User Image Stonkmoon Posted - 16 hours ago

$TAK 2021-10-27 09:15 ET Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors https://stonkmoon.com/news/TAK/61625ebd7da0220d54d14445426297fa

User Image Quantisnow Posted - 16 hours ago

$TAK 📰 Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors https://quantisnow.com/insight/1920447?s=s 30 seconds delayed.

User Image Stock_Titan Posted - 16 hours ago

$TAK Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors https://www.stocktitan.net/news/TAK/takeda-to-acquire-gamma-delta-therapeutics-to-accelerate-development-mafqm0i2x06k.html

User Image Newsfilter Posted - 16 hours ago

$TAK $TYO:4502 Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors https://newsfilter.io/a/1317a3bda7d1e86085fd96c32afce522

User Image jaydilks Posted - 17 hours ago

$ARKG It’s tough to quantify but about 7 of their holdings that have been (Cash Like) have just paid out their 3rd quarter dividends which ARKG gets and redeploys in buying without needing to sell stocks. There’s a point where they get aggressive dumping “Cash Like” holdings and go full on, risk on. At #13 is $TAK that pays a 6.04% Dividend. Takeda is a real head scratcher as it’s underperformed, the dividend has increased and they are leaning into Biotech. At some point you start to get the benefit of what those dividends paid two weeks ago and they grow with the risk on holdings. If they didn’t deploy them, ARKG likely has the biggest dividend of all the ARKs right after Christmas. I think it gives you (about) 2.65% wiggle room of being wrong on the price you buy shares today. If you are 2.65% wrong on where you buy, you either get that in a Dividend in December or that 2.65% grows by 5%. My point is, don’t worry about being perfect.

User Image cctranscripts Posted - 1 day ago

Major owner of Takeda Pharmaceutical Co., Ltd. just picked up 1,475,121 shares https://www.conferencecalltranscripts.com/summary/?id=10024260 $TAK

User Image Newsfilter Posted - 1 day ago

$TAK 1,475,121 shares acquired by Takeda Pharmaceutical Co Ltd (10% Owner), reported in a new form 4 filed with the SEC https://newsfilter.io/a/937b893a7718dfb5537544070e1ed46d

User Image STCKPRO Posted - 1 day ago

$TAK NEW ARTICLE : 2 of Sarah Ketterer's Stocks Sink Near 52-Week Lows https://www.stck.pro/news/TAK/17094759

User Image ChartMill Posted - 1 day ago

New 52 week lows for $PINS, $WU and $TAK https://www.chartmill.com/stock/stock-screener?f=p_pg10,v1_50b500,s2_nl,exch_us&v=3&utm_source=stocktwits&utm_medium=screener&utm_content=Stock_Screener:_New_52_week_low_today&utm_campaign=social_tracking

User Image hyperbolenarian Posted - 1 day ago

$TAK added 13.88

User Image tickeron Posted - 2 days ago

What do you think of this? $TAK's price moved below its 50-day Moving Average on September 28, 2021. View odds for this and other indicators: https://srnk.us/go/3120978

User Image Newsfilter Posted - 2 days ago

$SELB $TAK Selecta Biosciences announces at-the-market equity offering https://newsfilter.io/a/9d87ca8610ea4bde26e552e4a78c7079

User Image cctranscripts Posted - 2 days ago

Takeda Pharmaceuticals U.S.A., Inc. just provided an update on share ownership of Takeda Pharma https://www.conferencecalltranscripts.com/summary/?id=10015915 $TAK

User Image Newsfilter Posted - 2 days ago

$TAK Form SC 13G/A (statement of acquisition of beneficial ownership by individuals) filed with the SEC https://newsfilter.io/a/17f569c2ca56784314bda406dce8467b

User Image T8skmod Posted - 3 days ago

$TAK Tweet Stats Today's Change 38% + 🚀 https://t8sk.com/TAK

User Image StockOrbit Posted - 3 days ago

$TAK Earnings: Thursday, October 28 at 4:00 AM. The Options market is pricing in a 8.71% move. From $12.85(-8.71%) to $15.29(8.71%). Learn more on StockOrbit at https://apps.apple.com/us/app/stockorbit/id1541560646

User Image jaycarper Posted - 4 days ago

$TAK If I was CEO I would drop dividend and use money to buy a super growth up and coming biotech company, this will crash the stock but get that dead overhead supply out of the market and the stock could find a real bottom to build and grow from , also the investor base will change from people just using this as a money tree to sell stock putting downward pressure on the stock and buy other things to investors who buy and hold and wont sell because there is a real growth. The company is confused and has a mix investor base is it growth or is it slow and clunky cash machine where the stock never does anything like AT&T stock. Hard to serve two masters trying to make everyone happy makes no one happy in the end. Takeda needs to pick and go all in is it growth or is it cash machine with a strong focus on cost cutting .

User Image jaycarper Posted - 4 days ago

$TAK A tradable bottom is coming soon but not here... however the long term trend is lower :( sorry guys it is what it is too much hope and optimism still we need anger and despair no where close to that emotion yet even though we are will over 50% from its ATHs. Think about it if you bought at top your down 50% yet you still say it just needs to cool off, its okay, it will go back, come on it will be 85%-90% from the peak eventually and then we will get Anger, Fear, and hopelessness. Too many holders, too much supply, too much hope, a good company but a bad stock to trade or hold for now.

User Image marketchameleonwins Posted - 4 days ago

$TAK upcoming event October 26: PDUFA. Options expiring on November 19 that cover the event have an implied move of ±5.7% https://tinyurl.com/yhvpgkch

User Image Quantt Posted - 5 days ago

$CALA deal with $TAK is huge. Delayed market response to current price. My guess is delayed response when positive data comes out too. TAKEDA’s market cap in the billions interested in Penny stock? Something really big coming IMO.

Analyst Ratings
Morgan Stanley Equal-Weight Oct 7, 21
JP Morgan Overweight Mar 11, 20
Cowen & Co. Market Perform Nov 1, 19
Jefferies Buy Sep 24, 19